<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39416782</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>M protein ectodomain-specific immunity restrains SARS-CoV-2 variants replication.</ArticleTitle><Pagination><StartPage>1450114</StartPage><MedlinePgn>1450114</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1450114</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1450114</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">The frequent occurrence of mutations in the SARS-CoV-2 Spike (S) protein, with up to dozens of mutations, poses a severe threat to the current efficacy of authorized COVID-19 vaccines. Membrane (M) protein, which is the most abundant viral structural protein, exhibits a high level of amino acid sequence conservation. M protein ectodomain could be recognized by specific antibodies; however, the extent to which it is immunogenic and provides protection remains unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We designed and synthesized multiple peptides derived from coronavirus M protein ectodomains, and determined the secondary structure of specific peptides using circular dichroism (CD) spectroscopy. Enzyme-linked immunosorbent assay (ELISA) was utilized to detect IgG responses against the synthesized peptides in clinical samples. To evaluate the immunogenicity of peptide vaccines, BALB/c mice were intraperitoneally immunized with peptide-keyhole limpet hemocyanin (KLH) conjugates adjuvanted with incomplete Freund's adjuvant (IFA). The humoral and T-cell immune responses induced by peptide-KLH conjugates were assessed using ELISA and ELISpot assays, respectively. The efficacy of the S2M2-30-KLH vaccine against SARS-CoV-2 variants was evaluated in vivo using the K18-hACE2 transgenic mouse model. The inhibitory effect of mouse immune serum on SARS-CoV-2 virus replication in vitro was evaluated using microneutralization assays. The subcellular localization of the M protein was evaluated using an immunofluorescent staining method, and the Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) activity of the S2M2-30-specific monoclonal antibody (mAb) was measured using an ADCC reporter assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Seroconversion rates for ectodomain-specific IgG were observed to be high in both SARS-CoV-2 convalescent patients and individuals immunized with inactivated vaccines. To assess the protective efficacy of the M protein ectodomain-based vaccine, we initially identified a highly immunogenic peptide derived from this ectodomain, named S2M2-30. The mouse serum specific to S2M2-30 showed inhibitory effects on the replication of SARS-CoV-2 variants <i>in vitro</i>. Immunizations of K18-hACE2-transgenic mice with the S2M2-30-keyhole limpet hemocyanin (KLH) vaccine significantly reduced the lung viral load caused by B.1.1.7/Alpha (UK) infection. Further mechanism investigations reveal that serum neutralizing activity, specific T-cell response and Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) correlate with the specific immuno-protection conferred by S2M2-30.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">The findings of this study suggest that the antibody responses against M protein ectodomain in the population most likely exert a beneficial effect on preventing various SARS-CoV-2 infections.</AbstractText><CopyrightInformation>Copyright © 2024 Tang, Tang, Hu, Ye, Luo, Luo, Cao, Wang, Yue, Liu, Liu, Ge, Liu, Chen, Yuan and Deng.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Tang</LastName><ForeName>Yibo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hunan Provincial Key Laboratory of Medical Virology, College of Biology, Hunan University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tang</LastName><ForeName>Kaiming</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hu</LastName><ForeName>Yunqi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Public Health, Sun Yat-sen University, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Zi-Wei</ForeName><Initials>ZW</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Wanyu</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Public Health, Sun Yat-sen University, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Cuiting</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Hehe</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Infection and Virology, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Xinyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Public Health, Sun Yat-sen University, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dejian</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Hunan Provincial Key Laboratory of Medical Virology, College of Biology, Hunan University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Cuicui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hunan Provincial Key Laboratory of Medical Virology, College of Biology, Hunan University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Xingyi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Hunan Provincial Key Laboratory of Medical Virology, College of Biology, Hunan University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tianlong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yaoqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Public Health, Sun Yat-sen University, Shenzhen, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Medical Products Administration Key Laboratory for Quality Monitoring and Evaluation of Vaccines and Biological Products, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Shuofeng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hunan Provincial Key Laboratory of Medical Virology, College of Biology, Hunan University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Development Department, Beijing Weimiao Biotechnology Co. Ltd., Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086862">Coronavirus M Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000705510">membrane protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086862" MajorTopicYN="N">Coronavirus M Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014763" MajorTopicYN="Y">Viral Matrix Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody-dependent cellular cytotoxicity</Keyword><Keyword MajorTopicYN="N">cross-inhibition</Keyword><Keyword MajorTopicYN="N">membrane protein</Keyword><Keyword MajorTopicYN="N">serum neutralizing activity</Keyword></KeywordList><CoiStatement>Author LD was employed by company Beijing Weimiao Biotechnology Co. Ltd. Authors LD, YT, SY, YC, CL, Z-WY, YH, and DL are inventors of the patent application related to this study Patent applicant: Hunan University; Application No.: CN202210366334.5. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>4</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39416782</ArticleId><ArticleId IdType="pmc">PMC11480003</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1450114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, et al. . BNT162b2 protection against the omicron variant in children and adolescents. N Engl J Med. (2022) 386:1899–909. doi: 10.1056/NEJMoa2202826</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2202826</ArticleId><ArticleId IdType="pmc">PMC9006785</ArticleId><ArticleId IdType="pubmed">35353976</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Huo J, Zhou D, Zahradnik J, Supasa P, Liu C, et al. . SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. (2022) 185:467–484.e15. doi: 10.1016/j.cell.2021.12.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.046</ArticleId><ArticleId IdType="pmc">PMC8723827</ArticleId><ArticleId IdType="pubmed">35081335</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreno JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, et al. . Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. (2022) 602:682–8. doi: 10.1038/s41586-022-04399-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04399-5</ArticleId><ArticleId IdType="pubmed">35016197</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons. N Engl J Med. (2022) 386:698–700. doi: 10.1056/NEJMc2119236</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2119236</ArticleId><ArticleId IdType="pmc">PMC8781314</ArticleId><ArticleId IdType="pubmed">35021005</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Zhang R, Qiao S, Wang X, Zhang W, Ruan W, et al. . Omicron SARS-CoV-2 neutralization from inactivated and ZF2001 vaccines. N Engl J Med. (2022) 387:277–80. doi: 10.1056/NEJMc2206900</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206900</ArticleId><ArticleId IdType="pmc">PMC9342420</ArticleId><ArticleId IdType="pubmed">35793198</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A, et al. . Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect Dis. (2024) 24:e70–2. doi: 10.1016/s1473-3099(23)00744-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(23)00744-2</ArticleId><ArticleId IdType="pubmed">38109919</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu YZ, Wang SY, Zheng ZQ, Yi H, Li WW, Xu ZS, et al. . SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response. Cell Mol Immunol. (2021) 18:613–20. doi: 10.1038/s41423-020-00571-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00571-x</ArticleId><ArticleId IdType="pmc">PMC7588591</ArticleId><ArticleId IdType="pubmed">33110251</ArticleId></ArticleIdList></Reference><Reference><Citation>Boson B, Legros V, Zhou B, Siret E, Mathieu C, Cosset FL, et al. . The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles. J Biol Chem. (2021) 296:100111. doi: 10.1074/jbc.RA120.016175</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA120.016175</ArticleId><ArticleId IdType="pmc">PMC7833635</ArticleId><ArticleId IdType="pubmed">33229438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Nomura N, Muramoto Y, Ekimoto T, Uemura T, Liu K, et al. . Structure of SARS-CoV-2 membrane protein essential for virus assembly. Nat Commun. (2022) 13:4399. doi: 10.1038/s41467-022-32019-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32019-3</ArticleId><ArticleId IdType="pmc">PMC9355944</ArticleId><ArticleId IdType="pubmed">35931673</ArticleId></ArticleIdList></Reference><Reference><Citation>Naskalska A, Dabrowska A, Szczepanski A, Milewska A, Jasik KP, Pyrc K. Membrane protein of human coronavirus NL63 is responsible for interaction with the adhesion receptor. J Virol. (2019) 93:e00355–19. doi: 10.1128/jvi.00355-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00355-19</ArticleId><ArticleId IdType="pmc">PMC6744225</ArticleId><ArticleId IdType="pubmed">31315999</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopandić Z, Protić-Rosić I, Todorović A, Glamočlija S, Gnjatović M, Ćujic D, et al. . IgM and igG immunoreactivity of SARS-CoV-2 recombinant M protein. Int J Mol Sci. (2021) 22:4951. doi: 10.3390/ijms22094951</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094951</ArticleId><ArticleId IdType="pmc">PMC8125631</ArticleId><ArticleId IdType="pubmed">34066920</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. (2020) 395:565–74. doi: 10.1016/s0140-6736(20)30251-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)30251-8</ArticleId><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. (2020) 579:270–3. doi: 10.1038/s41586-020-2012-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorrissen P, Schutz P, Weiand M, Vollenberg R, Schrempf IM, Ochs K, et al. . Antibody response to SARS-CoV-2 membrane protein in patients of the acute and convalescent phase of COVID-19. Front Immunol. (2021) 12:679841. doi: 10.3389/fimmu.2021.679841</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.679841</ArticleId><ArticleId IdType="pmc">PMC8371319</ArticleId><ArticleId IdType="pubmed">34421894</ArticleId></ArticleIdList></Reference><Reference><Citation>Camerini D, Randall AZ, Trappl-Kimmons K, Oberai A, Hung C, Edgar J, et al. . Mapping SARS-CoV-2 antibody epitopes in COVID-19 patients with a multi-coronavirus protein microarray. Microbiol Spectr. (2021) 9:e0141621. doi: 10.1128/Spectrum.01416-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.01416-21</ArticleId><ArticleId IdType="pmc">PMC8549749</ArticleId><ArticleId IdType="pubmed">34704808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S, Xie XX, Zhao L, Wang B, Zhu J, Yang TR, et al. . The immunodominant and neutralization linear epitopes for SARS-CoV-2. Cell Rep. (2021) 34:108666. doi: 10.1016/j.celrep.2020.108666</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108666</ArticleId><ArticleId IdType="pmc">PMC7837128</ArticleId><ArticleId IdType="pubmed">33503420</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Zhou Y, Siddiqui P, Niu J, Jiang S. Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. J Clin Microbiol. (2005) 43:3718–26. doi: 10.1128/jcm.43.8.3718-3726.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.43.8.3718-3726.2005</ArticleId><ArticleId IdType="pmc">PMC1234014</ArticleId><ArticleId IdType="pubmed">16081901</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. (2022) 114:252–60. doi: 10.1016/j.ijid.2021.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.11.009</ArticleId><ArticleId IdType="pmc">PMC8595975</ArticleId><ArticleId IdType="pubmed">34800687</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Li J, Wang H, Wang F, Yin Z, Wang Z. Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis. BMC Med. (2023) 21:160. doi: 10.1186/s12916-023-02861-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-023-02861-3</ArticleId><ArticleId IdType="pmc">PMC10134725</ArticleId><ArticleId IdType="pubmed">37106390</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. . Development of an inactivated vaccine candidate, BBIBP-corV, with potent protection against SARS-CoV-2. Cell. (2020) 182:713–721.e9. doi: 10.1016/j.cell.2020.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.008</ArticleId><ArticleId IdType="pmc">PMC7275151</ArticleId><ArticleId IdType="pubmed">32778225</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, Ye ZW, Liang R, Tang K, Zhang AJ, Lu G, et al. . Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. Science. (2022) 377:428–33. doi: 10.1126/science.abn8939</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn8939</ArticleId><ArticleId IdType="pubmed">35737809</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. . Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. (2020) 25:2000045. doi: 10.2807/1560-7917.Es.2020.25.3.2000045</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.Es.2020.25.3.2000045</ArticleId><ArticleId IdType="pmc">PMC6988269</ArticleId><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH, et al. . Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-rdRp/hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. J Clin Microbiol. (2020) 58:e00310–20. doi: 10.1128/jcm.00310-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.00310-20</ArticleId><ArticleId IdType="pmc">PMC7180250</ArticleId><ArticleId IdType="pubmed">32132196</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, Yin X, Meng X, Chan JF, Ye ZW, Riva L, et al. . Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature. (2021) 593:418–23. doi: 10.1038/s41586-021-03431-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03431-4</ArticleId><ArticleId IdType="pubmed">33727703</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, Wang R, Chan JF, Zhang AJ, Cheng T, Chik KK, et al. . Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat Microbiol. (2020) 5:1439–48. doi: 10.1038/s41564-020-00802-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-00802-x</ArticleId><ArticleId IdType="pubmed">33028965</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi W, Tang K, Chen G, Xie Y, Polizzi NF, DeGrado WF, et al. . An enhanced broad-spectrum peptide inhibits Omicron variants in vivo . Cell Rep Med. (2024) 5:101418. doi: 10.1016/j.xcrm.2024.101418</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2024.101418</ArticleId><ArticleId IdType="pmc">PMC10897629</ArticleId><ArticleId IdType="pubmed">38340726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye ZW, Ong CP, Tang K, Fan Y, Luo C, Zhou R, et al. . Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. Cell Mol Immunol. (2022) 19:588–601. doi: 10.1038/s41423-022-00855-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-022-00855-4</ArticleId><ArticleId IdType="pmc">PMC8961489</ArticleId><ArticleId IdType="pubmed">35352010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WS, Selva KJ, Davis SK, Wines BD, Reynaldi A, Esterbauer R, et al. . Decay of Fc-dependent antibody functions after mild to moderate COVID-19. Cell Rep Med. (2021) 2:100296. doi: 10.1016/j.xcrm.2021.100296</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100296</ArticleId><ArticleId IdType="pmc">PMC8106889</ArticleId><ArticleId IdType="pubmed">33997824</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand SP, Prévost J, Nayrac M, Beaudoin-Bussières G, Benlarbi M, Gasser R, et al. . Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. Cell Rep Med. (2021) 2:100290. doi: 10.1016/j.xcrm.2021.100290</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100290</ArticleId><ArticleId IdType="pmc">PMC8097665</ArticleId><ArticleId IdType="pubmed">33969322</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Wang M, Zhang X, Li S, Lu Q, Zeng H, et al. . Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. Signal Transduct Target Ther. (2021) 6:346. doi: 10.1038/s41392-021-00759-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00759-1</ArticleId><ArticleId IdType="pmc">PMC8463587</ArticleId><ArticleId IdType="pubmed">34561414</ArticleId></ArticleIdList></Reference><Reference><Citation>Kared H, Wolf AS, Alirezaylavasani A, Ravussin A, Solum G, Tran TT, et al. . Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults. Nat Commun. (2022) 13:4165. doi: 10.1038/s41467-022-31888-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31888-y</ArticleId><ArticleId IdType="pmc">PMC9293966</ArticleId><ArticleId IdType="pubmed">35851055</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, et al. . Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. (2022) 608:603–8. doi: 10.1038/s41586-022-05053-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05053-w</ArticleId><ArticleId IdType="pmc">PMC9385487</ArticleId><ArticleId IdType="pubmed">35790190</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein S, Cortese M, Winter SL, Wachsmuth-Melm M, Neufeldt CJ, Cerikan B, et al. . SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography. Nat Commun. (2020) 11:5885. doi: 10.1038/s41467-020-19619-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19619-7</ArticleId><ArticleId IdType="pmc">PMC7676268</ArticleId><ArticleId IdType="pubmed">33208793</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD, et al. . SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell. (2020) 183:1043–1057.e15. doi: 10.1016/j.cell.2020.09.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.033</ArticleId><ArticleId IdType="pmc">PMC7489987</ArticleId><ArticleId IdType="pubmed">32970989</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YQ, Lan LY, Huang M, Henry C, Wilson PC. Hemagglutinin stalk-reactive antibodies interfere with influenza virus neuraminidase activity by steric hindrance. J Virol. (2019) 93:e01526–18. doi: 10.1128/jvi.01526-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01526-18</ArticleId><ArticleId IdType="pmc">PMC6364013</ArticleId><ArticleId IdType="pubmed">30518651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik I, Angeletti D, Gibbs JS, Angel M, Takeda K, Kosikova M, et al. . Neuraminidase inhibition contributes to influenza A virus neutralization by anti-hemagglutinin stem antibodies. J Exp Med. (2019) 216:304–16. doi: 10.1084/jem.20181624</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20181624</ArticleId><ArticleId IdType="pmc">PMC6363425</ArticleId><ArticleId IdType="pubmed">30683737</ArticleId></ArticleIdList></Reference><Reference><Citation>Eymieux S, Uzbekov R, Rouillé Y, Blanchard E, Hourioux C, Dubuisson J, et al. . Secretory vesicles are the principal means of SARS-CoV-2 egress. Cells. (2021) 10:2047. doi: 10.3390/cells10082047</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10082047</ArticleId><ArticleId IdType="pmc">PMC8393858</ArticleId><ArticleId IdType="pubmed">34440816</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques-Pereira C, Pires MN, Gouveia RP, Pereira NN, Caniceiro AB, Rosário-Ferreira N, et al. . SARS-CoV-2 membrane protein: from genomic data to structural new insights. Int J Mol Sci. (2022) 23:2986. doi: 10.3390/ijms23062986</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23062986</ArticleId><ArticleId IdType="pmc">PMC8948900</ArticleId><ArticleId IdType="pubmed">35328409</ArticleId></ArticleIdList></Reference><Reference><Citation>Siu YL, Teoh KT, Lo J, Chan CM, Kien F, Escriou N, et al. . E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol. (2008) 82:11318–30. doi: 10.1128/jvi.01052-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01052-08</ArticleId><ArticleId IdType="pmc">PMC2573274</ArticleId><ArticleId IdType="pubmed">18753196</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. (2015) 1282:1–23. doi: 10.1007/978-1-4939-2438-7_1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-2438-7_1</ArticleId><ArticleId IdType="pmc">PMC4369385</ArticleId><ArticleId IdType="pubmed">25720466</ArticleId></ArticleIdList></Reference><Reference><Citation>Godeke GJ, de Haan CA, Rossen JW, Vennema H, Rottier PJ. Assembly of spikes into coronavirus particles is mediated by the carboxy-terminal domain of the spike protein. J Virol. (2000) 74:1566–71. doi: 10.1128/jvi.74.3.1566-1571.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.74.3.1566-1571.2000</ArticleId><ArticleId IdType="pmc">PMC111495</ArticleId><ArticleId IdType="pubmed">10627571</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesev EV, LeDesma RA, Ploss A. Decoding type I and III interferon signalling during viral infection. Nat Microbiol. (2019) 4:914–24. doi: 10.1038/s41564-019-0421-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-019-0421-x</ArticleId><ArticleId IdType="pmc">PMC6554024</ArticleId><ArticleId IdType="pubmed">30936491</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. (2018) 18:545–58. doi: 10.1038/s41577-018-0029-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-018-0029-z</ArticleId><ArticleId IdType="pmc">PMC6340644</ArticleId><ArticleId IdType="pubmed">29921905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo M. T follicular helper and T(H)2 cells in allergic responses. Allergol Int. (2017) 66:377–81. doi: 10.1016/j.alit.2017.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.alit.2017.04.006</ArticleId><ArticleId IdType="pubmed">28499720</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YJ, Goretzki A, Schülke S. Immune metabolism of IL-4-activated B cells and th2 cells in the context of allergic diseases. Front Immunol. (2021) 12:790658. doi: 10.3389/fimmu.2021.790658</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.790658</ArticleId><ArticleId IdType="pmc">PMC8671807</ArticleId><ArticleId IdType="pubmed">34925372</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, et al. . The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. (2022) 185:447–456.e11. doi: 10.1016/j.cell.2021.12.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.032</ArticleId><ArticleId IdType="pmc">PMC8702401</ArticleId><ArticleId IdType="pubmed">35026151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, et al. . Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. (2023) 29:344–7. doi: 10.1038/s41591-022-02162-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02162-x</ArticleId><ArticleId IdType="pubmed">36473500</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>